

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Kumar *et al.*

Confirmation No.: 7447

Serial No.: 10/599,967

Group Art Unit: 1614

Filing Date: October 16, 2006

Examiner: A. Pagonakis

Title: CANCER TREATMENT COMBINATION COMPRISING A PYRIMIDINE
DERIVATIVE AND A QUINAZOLINE DERIVATIVE

MAIL STOP AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**AMENDMENT AFTER FINAL
SUBMITTED UNDER 37 CFR §1.116**

Sir:

This paper is being filed in response to the Final Office Action dated October 6, 2008. Examination of the application in view of the amendment and remarks following is earnestly solicited.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR §1.16 or §1.17, and any necessary extension of time fees, to Deposit Account No. 07-1392.

Remarks begin on page 2 of this paper.